Myovant Sciences, a newly-formed biotech developing an acquired therapy for endocrine disorders, raised $218 million by offering 14.5 million shares at $15, the high end of the range of $12 to $15. Myovant Sciences plans to list on the NYSE under the symbol...read more
AC Immune, a Swiss biotech developing therapies for Alzheimer's disease, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering. The Lausanne, Switzerland-based company was founded in 2003 and booked $39 million in sales for...read more
vTv Therapeutics, a biotech developing treatments for Alzheimer's disease and type 2 diabetes, announced terms for its IPO on Monday.
The High Point, NC-based company plans to raise $125 million by offering 7.8 million shares at a price range of $15 to $17....read more
Five IPOs raised $565 million this past week. The deals average +30% from the offer price, while none broke issue and most priced above the midpoint of the range.
...read more
Ending endocrine disorders: Myovant Sciences prices upsized IPO above the range at $15
Myovant Sciences, a newly-formed biotech developing an acquired therapy for endocrine disorders, raised $218 million by offering 14.5 million shares at $15, the high end of the range of $12 to $15. Myovant Sciences plans to list on the NYSE under the symbol...read more
Alzheimer's biotech AC Immune files for a $50 million IPO
AC Immune, a Swiss biotech developing therapies for Alzheimer's disease, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering. The Lausanne, Switzerland-based company was founded in 2003 and booked $39 million in sales for...read more
Alzheimer's biotech vTv Therapeutics sets terms for $125 million IPO
vTv Therapeutics, a biotech developing treatments for Alzheimer's disease and type 2 diabetes, announced terms for its IPO on Monday. The High Point, NC-based company plans to raise $125 million by offering 7.8 million shares at a price range of $15 to $17....read more
US IPO Weekly Recap: Wingstop unstoppable while massive biotech pops 99% then drops
Five IPOs raised $565 million this past week. The deals average +30% from the offer price, while none broke issue and most priced above the midpoint of the range. ...read more